Table 1 Baseline clinical indicators in the acute COVID-19 group (n = 66)

Indicators of fibrosis

 FIB-4 (IQR)

2.51 (1.30; 3.56)

–

  FIB-4 ≤ 1.45

35%

  FIB-4 1.46–3.24

27%

  FIB-4 ≥ 3.25

38%

 HA, ng/ml (IQR)

80.75 (45.94; 157.62)

–

  HA ≥ 75 ng/ml

54%

Enzymes

 ALT, U/l (IQR)

27 (18; 43)

–

  ALT > 40 U/l

29%

 AST, U/l (IQR)

35 (22; 50)

–

  AST > 40 U/l

38%

 LDH, U/l (IQR) (reference range 135–225)

288 (213; 416)

4

Blood cells

 WBC, × 10³/µl (IQR) (reference range 4.0–9.0)

5.12 (4.19; 6.84)

–

 RBC, × 10⁶/µl (IQR) (reference range: males 4.0–5.5, females 3.9–5.0)

4.58 (4.22; 4.90)

–

 Platelet, × 10³/µl (IQR) (reference range150–400)

185 (143; 229)

–

 CD4⁺ T lymphocytes, cells/mm³ (IQR)

471 (312; 646)

16

  CD4⁺  < 400 cells/mm³

42%

Inflammatory markers

 CRP, mg/l (IQR) (reference range < 5.0)

41.82 (12.34; 86.98)

–

 Ferritin, ng/ml (IQR) (reference range 30–400)

365.6 (171.3; 900.6)

1

 IL-6, pg/ml (IQR) (reference range < 5.0)

16.10 (8.15; 44.50)

13

 ESR, mm/h (IQR) (reference range < 20)

27.0 (18.0; 40.8)

2

Renal function

 Creatinine, µmol/l (IQR) (reference range: male 62–106, female 44–80)

75 (65; 93)

2

Oxygen saturation

 SpO₂ at admission, %

95 (91; 98)

9

 SpO₂ ≤ 93% at admission

30%

 Lowest SpO₂ during hospitalization

92 (88; 95)

3